Nautilus Biotechnology, Inc.
NASDAQ:NAUTBiotechnology
+$0.05 today
- Market cap
- $309.51M
- Beta
- 0.75
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.45
Volume 4.55M
Average 0.40M
NAUT Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Nautilus Biotechnology, Inc.NASDAQ: NAUT
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt turns positive
Q1 FY2026 net debt was $14.25M, compared with -$3.9M a year earlier.
Context
- Net debt amounted to 8.0% of total assets at the end of Q1 FY2026, up 6.3 pp from a year earlier.
- Net debt increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +465.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- 17.63M USD
- Year-over-year change
- +522.6%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.63M | +522.6% |
| FY2024 | 2024-12-31 | 2.83M | -81.4% |
| FY2023 | 2023-12-31 | 15.23M | +118.1% |
| FY2022 | 2022-12-31 | (84.2M) | +45.9% |
| FY2021 | 2021-12-31 | (155.59M) | — |
Net Debt vs competitors
How NAUT compares with its peers on the latest reported figures
- NAUT's Mar 2026 net debt of $14.25M is the 4th highest of the 11 companies compared; the peer median is -$32.61M.
- Its year-over-year change of +465.6% is the 2nd highest of 11, against a peer median of -5.1%.
- Net debt amounts to 8.0% of total assets for NAUT, versus a peer median of 27.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.68B | +11687.6% | — | 1.7% | |
| Mar 2026 | $151.69M | -2.7% | — | 48.2% | |
| Mar 2026 | $17.36M | +136.9% | — | 15.7% | |
| Mar 2026 | $14.25M | +465.6% | — | 8.0% | |
| Mar 2026 | $11.02M | +55.6% | — | 17.1% | |
| Mar 2026 | -$28.63M | -40.4% | — | 12.2% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | -$36.59M | +43.4% | — | 34.0% |
| Mar 2026 | -$46.92M | -79.3% | — | 21.1% | |
| Mar 2026 | -$70.77M | -73.2% | — | 52.4% | |
| Mar 2026 | -$187.39M | -7.5% | — | 76.4% | |
ZURAZura Bio Limited | Mar 2026 | -$225.59M | -32.3% | — | 98.7% |
| Peer median (excluding NAUT) | -$32.61M | -5.1% | — | 27.5% | |
Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 185.62M | 114.52M | 19.4M | 27.65M | 12.39M |
| Short-term Investments | 160.11M | 69.95M | 154.02M | 102.25M | 91.02M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 3.42M | 2.93M | 2.56M |
| Total Current Assets | 349.22M | 187.21M | 176.84M | 132.83M | 105.96M |
| Property, Plant & Equipment (Net) | 31.86M | 32.57M | 36.9M | 32.33M | 31.23M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 16.37M | 129.17M | 90.65M | 76.41M | 52.74M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 997K | 1.11M | 1.18M | 1.18M | 1.18M |
| Total Non-current Assets | 49.23M | 162.84M | 128.73M | 109.92M | 85.15M |
| Total Assets | 398.45M | 350.05M | 305.57M | 242.74M | 191.11M |
| Account Payables | 1.72M | 1.27M | 1.64M | 987K | 943K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 388K | 438K | 2.97M | 1.86M | 2.7M |
| Total Current Liabilities | 5.81M | 6.79M | 9.12M | 7.63M | 7.95M |
| Long-term Debt | 0 | 0 | 0 | 0 | 26.19M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 29.06M | 28.34M | 31.09M | 26.38M | 26.19M |
| Total Liabilities | 34.87M | 35.13M | 40.21M | 34.01M | 34.14M |
| Common Stock | 12K | 12K | 13K | 13K | 13K |
| Retained Earnings | (80.64M) | (138.56M) | (202.24M) | (273.02M) | (332.02M) |
| Accumulated OCI | (184K) | (1.85M) | (255K) | 57K | 243K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 363.58M | 314.92M | 265.35M | 208.73M | 156.97M |
| Total Debt | 30.03M | 30.33M | 34.63M | 30.48M | 30.02M |
| Net Debt | (155.59M) | (84.2M) | 15.23M | 2.83M | 17.63M |
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
Intrinsic Alpha fair value
Locked
Current Price
$2.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.